Prohibit anti-competitive deals – “pay-for-delay” deals – between brand and generic drug makers.
Brand name drug companies sometimes try to delay their competition by paying generic drug makers to stay off the market. When these deals occur, drug prices stay high, costing patients and taxpayers more money.
The Sanders plan prohibits these pay-for-delay deals. According to the Federal Trade Commission, these anticompetitive deals cost consumers and taxpayers at least $3.5 billion in higher drug costs every year.